Acadia Pharmaceuticals to Participate in the UBS Virtual CNS Day
13 Marzo 2024 - 2:05PM
Business Wire
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that
it will participate in the UBS Virtual CNS Day on Monday, March 18,
2024 at 2:00 p.m. Eastern Time.
The conference will be held virtually. A live webcast of
Acadia’s presentation will be accessible on the company’s website,
Acadia.com, under the investors section and an archived recording
will be available on the website for approximately one month
following the presentation.
About Acadia Pharmaceuticals
Acadia is advancing breakthroughs in neuroscience to elevate
life. For 30 years we have been working at the forefront of
healthcare to bring vital solutions to people who need them most.
We developed and commercialized the first and only FDA-approved
drug to treat hallucinations and delusions associated with
Parkinson’s disease psychosis and the first and only FDA-approved
drug for the treatment of Rett syndrome. Our clinical-stage
development efforts are focused on treating Prader-Willi syndrome,
Alzheimer’s disease psychosis and multiple other programs targeting
neuropsychiatric symptoms in central nervous system disorders. For
more information, visit us at Acadia.com and follow us on LinkedIn
and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240313546332/en/
Investor Contact: Acadia Pharmaceuticals Inc. Al Kildani (858)
261-2872 ir@acadia-pharm.com
Acadia Pharmaceuticals Inc. Jessica Tieszen (858) 261-2950
ir@acadia-pharm.com
Acadia Pharmaceuticals (NASDAQ:ACAD)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Acadia Pharmaceuticals (NASDAQ:ACAD)
Gráfica de Acción Histórica
De May 2023 a May 2024